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The human chromosome 7p21 locus harbors a major
gene that influences variation of glomerular filtration
rate and development of end-stage renal disease. The
pro-inflammatory IL-6 cytokine is a candidate gene since
chronic inflammation has been implicated in diabetic
nephropathy and this gene is located under the peak of
linkage. To test this, single nucleotide polymorphism (SNP)
and haplotype analyses were performed using a case-control
study of 295 patients consisting of 138 with proteinuria,
157 with chronic renal failure and these were compared
to174 control patients with normal albumin excretion.
Five tagging SNPs were selected for analysis based on
linkage disequilibrium patterns and proximity to the
functionally important 634G4C SNP in the IL-6 promoter.
Initial analysis suggested that a 174G4C polymorphism
may be associated with risk of chronic renal failure but
this was not significant after Bonferroni correction. While
haplotype analyses showed no association with proteinuria;
a significant association with chronic renal failure was found.
There was significantly more of the GGGAGC haplotype
among patients with chronic renal failure compared to
controls and this association remained significant even after
correction for multiple testing. Our study has found a specific
IL-6 haplotype conferring risk for impaired renal function
in patients with type 2 diabetes.
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Diabetic nephropathy and its related traits including end-
stage renal disease (ESRD) and variation in GFR (glomerular
filtration rate) are strongly determined by genes.1 Two recent
genome scans revealed evidence for such a gene locus on
human chromosome 7p21.2,3 Ordered subset analysis showed
significant evidence for linkage with ESRD (logarithm of
odds; LOD¼ 3.6) in the 37% of African-American families
with longest duration of type II diabetes before the onset of
renal failure.3 In a more recent study on families with type II
diabetes,2 variation in GFR as estimated by serum cystatin C
was also linked to this same locus (LOD¼ 4.0) with the peak
of linkage colocalizing almost exactly with that reported
by Bowden et al.3 Inspection of the critical region closely
underneath the peak of linkage revealed interleukin-6 (IL-6)
as a prime positional candidate gene.
Interleukin-6 is a key pro-inflammatory cytokine pro-
duced by a variety of cell types including glomerular
mesangial cells.4,5 Functionally, IL-6 regulates the production
of cell adhesion and chemotactic molecules, and mediates the
release of other cytokines that amplify the inflammatory
response.6,7 Molecular dissection of the IL-6 promoter has
implicated several single-nucleotide polymorphisms (SNPs)
as having functional importance, particularly 174G4C
(rs1800795) and 634G4C (rs1800796) SNPs. In HeLa cells,
the rs1800795 C reporter gene construct was found to exhibit
lower gene expression compared with the rs1800795 G
construct. Furthermore, stimulation with lipopolysaccharide
or IL-1-upregulated gene expression from the rs1800795 G,
but not the C allele construct. Compared with the C allele,
the pro-inflammatory rs1800795 G allele was associated with
raised plasma levels of IL-6 in healthy subjects.8 The
functional importance of rs1800796 has likewise been
demonstrated. Carriage of the rs1800796 G allele has been
associated with higher IL-6 secretion in peripheral blood
mononuclear cells upon stimulated with lipopolysaccharide
or advanced glycation end product–bovine serum albumin.9
The control of IL-6 gene expression is, however, likely to
extend beyond just rs1800796 and rs1800795, and be
influenced by the presence of other polymorphisms at this
chromosomal locus.10
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The pathogenic role of chronic inflammation in a variety
of human diseases is well recognized.11 More recently, this
process has been implicated in the etiology of diabetic
complications.12 A culprit role for IL-6 in diabetic nephro-
pathy is supported by the observation that serum levels of
this cytokine were correlated with the severity of renal disease
among both type I and type II diabetic patients.13,14
Furthermore, macroalbuminuria in type II diabetic Japanese
patients has been associated with rs1800796 GG genotype.9
Another recent report found that among Asian Indians, the
risk of ESRD was associated with the rs1800795 GG
genotype, although ESRD was largely attributed to glomer-
ulonephritis.15
Taking into account these intriguing observations as well
as the results of linkage and association studies reported until
recently, we sought to investigate whether susceptibility to
advanced diabetic nephropathy including impaired renal
function could be explained by genetic variation at the
IL-6 locus. Because gene regulation of IL-6 is likely to be
complex,10 we sought to provide the first haplotype analysis
of this locus in relation to risk for this complication.
RESULTS
Patient characteristics
A total of 174 controls and 295 cases were analyzed in
this study. Both groups were similar in terms of gender
composition, age at diabetes diagnosis, and HbA1c values
(P¼NS) (Table 1). Besides being slightly older and having a
longer known diabetes duration (both Po0.0001), cases had
higher systolic blood pressure (Po0.0001) but slightly lower
diastolic blood pressure compared with controls (Po0.001)
(Table 1). In all, 53.2% (157/295) of cases had already
developed chronic renal failure (CRF)/ESRD by the time of
enrollment into this study.
Linkage disequilibrium and tagSNPs
Linkage disequilibrium across the IL-6 locus was assessed
using HapMap data for the Caucasian CEU samples. A total
of 12 SNPs (rs2068927, rs1800797, rs1800795, rs2069832,
rs2069833, rs1474348, rs2069837, rs1474347, rs2069840,
rs1554606, rs2069845, and rs2069861) were identified to be
polymorphic (minor allele frequency (MAF) X0.05). For
these, pairwise |D0|-values were high, and, therefore, they
were considered to be in a single haplotype block (Table S1).
To capture haplotype diversity, five tagSNPs were then
selected for genotyping (rs2069827, rs1800795, rs2069837,
rs2069840, and rs2069861). For completeness, rs1800796 was
included, although it has a low MAFo0.05, as it may have
functional significance.9
Single SNP and haplotype analyses
Genotype distributions of all six SNPs were in Hardy–Wein-
berg equilibrium when assessed according to individual renal
comparison groups except for both rs2069827 (P¼ 0.0084)
and rs1800795 (P¼ 0.0009) among cases with CRF/ESRD.
The P-value for rs1800795 remained significant at 0.0162
after employing Bonferroni’s correction for 18 comparisons.
Genotype–disease associations were analyzed separately
according to whether cases had proteinuria or CRF/ESRD
(Table 2). None of the SNPs showed any significant
association with the presence of proteinuria. However,
rs1800795, which had been reported to be associated with
ESRD,15 showed borderline evidence for an association with
CRF/ESRD (P¼ 0.0280) but not proteinuria (P¼ 0.6477).
From a statistically conservative standpoint, this positive
association with CRF/ESRD did not remain significant after
correction for 12 comparisons (P¼ 0.3360). Consideration of
potentially important covariates including age, gender, blood
pressure, glycaemic control, and diabetes duration did not
affect SNP–disease association (data not shown). There was
no significant association between any of the SNPs and
advanced diabetic nephropathy (proteinuria and CRF/ESRD
combined) with the smallest P-value¼ 0.1266 (Table 2).
We next performed haplotype analyses using all six SNPs
(rs2069827, rs1800796, rs1800795, rs2069837, rs2069840, and
rs2069861). No haplotype was found to be significantly
associated with the combined traits of proteinuria and
CRF/ESRD after correction for multiple hypothesis testing
(Table 3). As with the single SNP analysis, no association was
found with proteinuria alone. In contrast, there was evidence
for an association with CRF/ESRD. Specifically, there was
an excess of the G-G-G-A-G-C haplotype among cases
with CRF/ESRD (25.5%) compared with controls (15.4%)
(P¼ 0.0016) (Table 3). This risk haplotype is one out of
three at the IL-6 locus that bore both rs1800795 G and
rs1800796 G pro-inflammatory alleles, and its disease
association remained statistically significant even after a
conservative Bonferroni’s correction for 14 haplotype–trait
comparisons (P¼ 0.0224).
Additional haplotype analyses were performed after exclud-
ing rs1800796, so that only the five tagging SNPs (rs2069827,
rs1800795, rs2069837, rs2069840, and rs2069861) were studied.
In all haplotype–trait comparisons, no significant association
was found after correction for multiple hypotheses testing
(Table S2).
Table 1 | Patient characteristics
Clinical characteristics Controls Cases P-value
Number (n) 174 295
Gender (male/female) 99/75 179/116 NS
Age at diabetes diagnosis (years) 42 (9) 43 (8) NS
At the enrollment into the study:
Age (years) 57 (8) 61 (8) o0.0001
BMI (kg/m2) 30 (16) 32 (7) NS
Known duration of diabetes (years) 13 (7) 17 (8) o0.0001
Hemoglobin A1c (%) 7.9 (1.4) 8.0 (1.6) NS
Systolic blood pressure (mm Hg) 129 (15) 137 (20) o0.0001
Diastolic blood pressure (mm Hg) 85 (23) 79 (18) o0.001
Cases with CRF/ESRD (n) NA 157
BMI, body mass index; CRF, chronic renal failure; ESRD, end-stage renal disease; NA,
not applicable; NS, not significant.
Data are presented as mean (s.d.).
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DISCUSSION
Emerging evidence suggests that IL-6 is important in confer-
ring genetic susceptibility to a host of human diseases inclu-
ding cancer,16 metabolic syndrome,17 systemic-onset juvenile
chronic arthritis,8 and osteoporosis.18 In this study, we have
extended these observations by providing evidence that IL-6
is a susceptibility gene for advanced diabetic nephropathy in
type II diabetes. Particularly, there was a highly significant
finding that pointed to the presence of a specific risk
haplotype for impaired renal function in type II diabetes
(P¼ 0.0016). With a conservative Bonferroni’s correction,
this genetic association still remained statistically significant.
In contrast, analyses at the level of single SNPs did not
revealed any clear evidence for association with advanced
diabetic nephropathy even though two of the SNPs
(rs1800796 and rs1800795) are thought to have functional
significance.
The observation that the genotype distribution of
rs1800795 deviated from Hardy–Weinberg equilibrium only
in the CRF/ESRD group is consistent with the selective
enrichment of the G allele with respect to this phenotype.
Indeed, the association with CRF/ESRD did reach nominal
significance (P¼ 0.028). This SNP is, however, unlikely to
explain the linkage signal for ESRD on human chromosome
7p21 as has been reported in type II diabetic African
Americans,3 because this SNP is largely monomorphic in this
ethnic group. Indeed, a search through dbSNP (http://www.
ncbi.nlm.nih.gov/SNP/index.html) quickly revealed that
the frequency of the G risk allele ranged from 96 to 100%
among African Americans. This preponderance of the G allele
is also seen in other human populations such as Chinese
(100%), Japanese (100%), Hispanics (80%), and even sub-
Saharan Africans (100%). Thus, if the IL-6 locus does indeed
confer susceptibility to impaired renal function among
diabetic patients across different human populations, it is
likely that a risk haplotype bearing the rs1800795 G allele
is involved in conferring this risk. Although our study is
confined to Caucasians, the positive findings clearly provided
a reasonable basis to support this notion. The possibility
that this IL-6 haplotype may help explain the results
of a recent genome scan that showed linkage of GFR to
7p21 in Caucasian families with type II diabetes is certainly
intriguing and could be followed up upon in future
studies.2
Because our study suggested that genetic variation in IL-6
was associated with impaired renal function rather than type
II diabetes per se, one might have reasonably expected that
the frequencies of the rs1800795 GG genotype as well as the
GGGAGC haplotype among the proteinuric cases should be
intermediate between the normoalbuminuric controls and
the CRF/ESRD cases. Indeed, this would appear to be the case
with the rs1800795 GG genotype frequency rising from
Table 2 | Genotype distribution of IL-6 SNPs according to renal status
SNP Location Genotype CTRL
PROT/CRF/
ESRD PROT CRF/ESRD
CTRL vs
PROT/CRF/
ESRD: P-value
CTRL vs
PROT:
P-value
CTRL vs CRF/
ESRD: P-value
rs2069827 50-flanking
region
GG 153 (90.0) 247 (86.1) 112 (83.0) 135 (88.8) 0.2564 0.0706 0.1809
GT 17 (10.0) 37 (12.9) 23 (17.0) 14 (9.2)
TT 0 (0.0) 3 (1.0) 0 (0.0) 3 (2.0)
170 (100.0) 287 (100.0) 135 (100.0) 152 (100.0)
rs1800796 50-flanking
region
CC 4 (2.4) 4 (1.4) 3 (2.2) 1 (0.6) 0.7344 0.9970 0.4414
CG 24 (14.1) 43 (14.9) 19 (14.1) 24 (15.7)
GG 142 (83.5) 241 (83.7) 113 (83.7) 128 (83.7)
170 (100.0) 288 (100.0) 135 (100.0) 153 (100.0)
rs1800795 50-flanking
region
CC 22 (13.1) 38 (13.4) 14 (10.6) 24 (15.8) 0.1535 0.6477 0.0280*
CG 74 (44.1) 100 (35.2) 55 (41.7) 45 (29.6)
GG 72 (42.9) 146 (51.4) 63 (47.7) 83 (54.6)
168 (100.0) 284 (100.0) 132 (100.0) 152 (100.0)
rs2069837 Intron 2 AA 141 (83.4) 232 (81.1) 111 (82.2) 121 (80.1) 0.8247 0.9560 0.7455
AG 27 (16.0) 52 (18.2) 23 (17.0) 29 (19.2)
GG 1 (0.6) 2 (0.7) 1 (0.7) 1 (0.7)
169 (100.0) 286 (100.0) 135 (100.0) 151 (100.0)
rs2069840 Intron 3 CC 24 (14.0) 25 (8.7) 15 (11.2) 10 (6.6) 0.1266 0.0820 0.0904
GC 60 (35.1) 120 (42.0) 64 (47.8) 56 (36.8)
GG 87 (50.9) 141 (49.3) 55 (41.0) 86 (56.6)
171 (100.0) 286 (100.0) 134 (100.0) 152 (100.0)
rs2069861 30-flanking
region
CC 143 (84.1) 256 (89.5) 122 (90.4) 134 (88.7) 0.1487 0.1067 0.2292
CT 27 (15.9) 29 (10.1) 12 (8.9) 17 (11.3)
TT 0 (0.0) 1 (0.4) 1 (0.7) 0 (0.0)
170 (100.0) 286 (100.0) 135 (100.0) 151 (100.0)
CRF/ESRD, cases with chronic renal failure/end-stage renal disease; CTRL, controls; IL-6, interleukin; PROT, cases with proteinuria; SNP, single-nucleotide polymorphism.
*P=0.3360 after Bonferroni’s correction for 12 comparisons.
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42.9% (CTRL) to 47.7% (PROT) and to 54.6% (CRF/ESRD)
(Table 2). Similarly, the frequency of the GGGAGC haplotype
rose from 15.4% (CTRL) to 16.7% (PROT) and to 25.5%
(CRF/ESRD) (Table 3). With the largest difference being
observed with the CRF/ESRD group, the effect of IL-6 gene
variation seemed primarily to be on the development of CRF/
ESRD rather than proteinuria. The intermediate frequency
among the PROT group is potentially due to the fact that a
limited subset of these cases may subsequently go on to
develop CRF/ESRD.
Our findings are discordant to that of a previous report
that found that there was an association of the rs1800796 GG
genotype with macroalbuminuria in Japanese patients with
type II diabetes.9 Interestingly, although this SNP is common
in Asians, the reverse is true in Caucasians. The rarity of this
SNP does reduce the power of our study to detect a potential
association, but it should be emphasized that the prevalence
of the rs1800796 GG genotype is virtually identical across the
renal comparison groups. This suggested that the magnitude
of this genotypic effect is absent or miniscule at best in our
study population.
A point worth noting is that our most significant findings
came from the haplotype analyses that incorporated all five
tagging SNPs as well as reportedly functional SNP rs1800796.
Although the latter was not required as a tagging SNP, its
fortuitous inclusion turned out to be important. Specifically,
this SNP allowed the risk G-G-G-A-G-C haplotype to be
distinguished from the closely related G-C-G-A-G-C haplo-
type, which itself did not show any disease association
(Table 3).
Our study has several strengths. First, we used a
case–control collection that has been assembled following
the sound epidemiological principle that cases and controls
should be recruited from the same source population.19
Specifically, all cases and controls were recruited from among
patients attending the Joslin Clinic, and this reduced the
possibility of potential bias or confounding that may arise
when cases and controls are collected from separate sites.
Although the possibility of population stratification in this
patient collection has yet to be fully evaluated by analyzing
large numbers of SNPs neutral to the phenotype of interest,
we have undertaken practical steps to minimize this potential
source of confounding by restricting our study to Caucasians
residing in Massachusetts and attending the Clinic. Impor-
tantly, it is reassuring that previous positive results obtained
using this collection has been confirmed in other inde-
pendent studies.20 Second, our cases consisted of those
with proteinuria alone as well as those with CRF/ESRD, and,
as such, we were able to test for associations with these
subphenotypes. Third, we adopted a conservative position
seldom taken in genetic association studies by accounting for
multiple comparisons using the Bonferroni’s procedure. This
gave us confidence that the association between the G-G-G-
A-G-C risk haplotype and CRF/ESRD was likely a true
finding.
A few potential limitations should be highlighted. Super-
ficially, the requirement for a minimum known diabetes
duration of at least 7 years among controls may seem to be
relatively short especially, because in our previous studies on
type I diabetic patients, we had employed a minimal duration
of 15 years.21 However, it is well established that the onset of
type II diabetes is insidious, and, as such, patients are gene-
rally diagnosed only after 5–10 years after the actual onset of
disease. Thus, in reality, the actual duration of diabetes in our
controls would be closer to 12 years or more. In this
connection, it may be highlighted that in a comprehensive
meta-analysis of 47 studies comprising 14,727 subjects on the
association between the angiotensin-I-converting enzyme I/D
polymorphism and diabetic nephropathy, no obvious benefit
was observed by requiring controls to have a long-known
diabetes duration.22 This observation is consistent with
the fact that most type II diabetic patients would already
have had the disease for a significant period of time before
diagnosis.
A second potential limitation is the possibility that some
of our cases may have nondiabetic renal disease because
renal biopsies are not routinely performed in clinical
practice to diagnose diabetic nephropathy. However, Oslen
and Mogensen23 have earlier concluded in their careful
review of their own data as well as nine published studies
Table 3 | IL-6 haplotype distribution according to renal status
CTRL PROT+CRF/ESRD PROT CRF/ESRD
CTRL vs PROT+
CRF/ESRD
CTRL vs
PROT
CTRL vs
CRF/ESRD
Haplotypea
Frequency
(%) 95% CI
Frequency
(%) 95% CI
Frequency
(%) 95% CI
Frequency
(%) 95% CI
Haplotype-
specific
P-value
Global
P-value
Haplotype-
specific
P-value
Global
P-value
Haplotype-
specific
P-value
Global
P-value
G-G-C-A-G-C 22.0 17.7–26.4 18.2 15.0–21.3 17.9 13.4–22.5 18.6 14.2–22.9 0.1505 0.1450 0.1953 0.5029 0.2473 0.0397
G-G-C-A-G-T 8.0 5.1–10.8 5.4 3.6–7.3 5.2 2.5–7.8 5.7 3.1–8.3 0.1033 0.1545 0.1947
G-G-G-A-C-C 31.6 26.7–36.5 29.2 25.5–32.9 33.9 28.2–39.6 25.0 20.2–29.8 0.5225 0.5373 0.1049
G-G-G-A-G-C 15.4 11.6–19.2 21.4 18.1–24.8 16.7 12.2–21.1 25.5 20.6–30.4 0.0300# 0.6804 0.0016w
G-G-G-G-G-C 8.6 5.6–11.5 9.1 6.8–11.5 8.0 4.8–11.3 10.2 6.8–13.6 0.8597 0.8801 0.6787
G-C-G-A-G-C 9.4 6.3–12.5 8.5 6.2–10.8 8.7 5.1–11.8 8.5 5.4–11.6 0.5350 0.6155 0.5897
T-G-C-A-G-C 5.0 2.7–7.3 6.9 4.8–8.9 7.1 4.1–10.2 6.5 3.8–9.3 0.3413 0.3763 0.4312
Total 100.0 98.9 97.5 100.0
CRF/ESRD, cases with chronic renal failure/end-stage renal disease; CTRL, controls; IL-6, interleukin; PROT, cases with proteinuria.
aHaplotypes with estimated frequencies o1% are excluded. Haplotypes are formed from rs2069827, rs1800796, rs1800795, rs2069837, rs2069840, and rs2069861.
#Not significant for correction for seven haplotype–trait comparisons.
wP=0.0244 after correction for a total of seven haplotype–PROT and seven haplotype–CRF/ESRD comparisons.
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that nondiabetic renal disease occurs only in a minority of
type II diabetic patients. More recent studies demonstrate
that even in the absence of concomitant diabetic retinopathy,
the majority (70–74%) of albuminuric type II diabetic
patients do indeed have diabetic glomerulopathy.24,25 We
agree that although it is difficult to completely eradicate
disease misclassification in genetic association studies on
diabetic nephropathy, our success in identifying the IL-6 risk
haplotype certainly suggested that misclassification (either in
cases or controls) was not a major issue, because substantial
misclassification will inadvertently have the effect of driving
such an association toward the null.
A third limitation is that our sample size is moderate
especially when compared with, for instance, that needed
for GWAS (genome-wide association studies). However,
this difference in sample size requirement is related to the
fact that up to a million SNPs are tested in GWAS, and each
SNP has an extremely low a priori probability of disease
association. The large sample size is, therefore, needed in
GWAS to produce very small P-values but after taking into
account the huge number of hypotheses tested, only a few
potential associations will remain nominally significant. Such
an extreme situation, however, does not exist in our current
study. Instead, we employed a focused approach by studying
select tagging SNPs in a candidate gene that has been
implicated in the pathogenesis of diabetic nephropathy.
Moreover, this gene is located in a chromosomal region
linked to impaired renal function and this may have
heightened the a priori probability of a true genetic
association. Indeed, our results would appear to have borne
witness to this with strong evidence of a haplotype–disease
association that withstood conservative statistical correction.
Furthermore, our calculations indicated that this study has
87% power to detect an association of the magnitude that
was observed between the risk haplotype and CRF/ESRD.
This suggested that our findings were quite unlikely due to
statistical chance despite the modest sample size. Still, as with
results from other genetic studies including WGAS, it is
imperative to independently replicate our promising findings
in other patient collections. Another limitation of our study
is that due to its case–control nature, it is not possible
to effectively address the potential issue of survival bias.
As such, future cohort studies with a substantial number of
incident cases of CRF/ESRD will be useful to independently
replicate our findings.
Finally, we currently do not know the functional
significance of this G-G-G-A-G-C risk haplotype with regard
to controlling IL-6 gene expression in diabetes. In vitro
studies have suggested that IL-6 haplotypes may cause
differential gene transcription in cell lines of epithelial
compared with those of endothelial origin.10 The direct
relevance of this finding has unfortunately not been
established in the diabetic kidney. It is perhaps noteworthy
that the risk haplotype does contain the pro-inflammatory
alleles for both 634G4C (rs1800796) and 174G4C
(rs1800795) SNPs. This might lead one to speculate that G
alleles of both SNPs may be required for the risk of CRF/
ESRD. Thus, in human populations (for example, Japanese,
Chinese, African American) that are largely monomorphic
for the 174G allele, increased disease risk would appear to
be associated with the 634 G allele. In Caucasians with a
low frequency of the 634 C allele, it would appear that the
174G4C SNP is potentially more important and that the
association was strengthened further in a haplotype analysis
that includes both SNPs. One may also postulate that coupled
with the presence of other genetic variation at the IL-6 locus,
a localized pro-inflammatory process may occur in certain
kidney cell types in diabetes culminating in impaired renal
function.
In conclusion, our study has yielded first evidence for an
IL-6 haplotype that confers risk for impaired renal function
in type II diabetes. This finding may potentially help explain
the results of linkage studies for diabetic nephropathy and its
related traits that have been previously been localized to
chromosome 7p21.
MATERIALS AND METHODS
Study groups
Since 1998, individuals with type II diabetes have been recruited for
studies of the genetics of nephropathy from among patients
attending the Joslin Clinic in Boston (MA, USA). Diabetes has
been classified as type II, if it was diagnosed between ages 35 and
64 years and was treated for at least 2 years with diet or oral
hypoglycemic agents. Only patients younger than 75 years of age
at enrollment are included in the study.
Diagnosis of diabetic nephropathy
Diabetic nephropathy was determined on the basis of the medical
records of the Joslin Clinic (supplemented with records of other
physicians if necessary), and results of routine urinary analyses,
including measurements of the ACR (albumin-to-creatinine
ratio).26 As the diagnosis of type II diabetes is generally established
many years after onset of hyperglycemia, patients were classified as
controls if they had type II diabetes with known duration of at least
7 years, and the ACR (in mg/g) waso17 (men) oro25 (women) in
at least two out of the last three urine specimens spanning at least a
2-year interval. Patients with microalbuminuria or intermittent
proteinuria were not included in this study. Patients were considered
cases if they had persistent proteinuria or if they had ESRD due to
diabetic nephropathy. Persistent proteinuria was defined as two out
of three successive urinalyses positive by either reagent strip (greater
than 2þ on Multistix; Bayer Corporation, Diagnostics Division,
Elkhart, IN, USA) or an ACR (in mg/g) greater than 250 (men) or
greater than 355 (women). Patients with persistent proteinuria and
serum creatinine greater than 2.0 mg/100 ml were considered as
cases with CRF. At the time of this study, genomic DNA was
available for 295 cases and 174 controls. Only Caucasians were
included in this study.
Examination of study participants
All patients selected for the genetic studies were examined at the
clinic or at their homes. After consenting to participate in the study,
each subject had a standardized physical examination and provided
a diabetes history regarding its diagnosis, treatment, and complica-
tions. Each individual provided a blood sample for biochemical
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measurements and DNA extraction. Patient medical records were
thoroughly reviewed to minimize the possibility of the presence
of nondiabetic kidney disease, and patients were also directly
questioned whether they were ever diagnosed for nondiabetic kidney
disease by physicians. The Committee on Human Subjects of the
Joslin Diabetes Center approved the protocols and informed consent
procedures for our studies.
Linkage disequilibrium analysis and the selection of
tagging SNPs
Linkage disequilibrium at the IL-6 locus was assessed based on
SNPs genotyped in the Hapmap Caucasian CEU samples
(http://www.hapmap.org). A total of 46 SNPs were genotyped in a
7.4-kb region that encompassed the entire 4.8-kb IL-6 gene. Of these,
34 SNPs (rs2069824, rs2069826, rs3087224, rs4335044, rs1800796,
rs2069857, rs2069829, rs13447445, rs2069830, rs1524107, rs2066992,
rs2069839, rs3087234, rs13306434, rs2069834, rs2069835, rs2069836,
rs2069838, rs3087235, rs13306433, rs2069842, rs1548216, rs2069843,
rs2069844, rs13306435, rs2069860, rs2069849, rs2069850, rs13306436,
rs2069851, rs2069852, rs2069853, rs2069854, and rs2069855) were not
polymorphic or had a low minor allele frequency (MAFo0.05) among
the CEU samples.
Pairwise |D0|- and r-values were computed for the 12 remaining
SNPs (rs2068927, rs1800797, rs1800795, rs2069832, rs2069833,
rs1474348, rs2069837, rs1474347, rs2069840, rs1554606, rs2069845,
and rs2069861). Haplotype blocks were defined as previously
described with |D0|X0.8 being taken as evidence of strong linkage
disequilibrium.27 Within the haplotype block, tagSNPs (rs2069827,
rs1800795, rs2069837, rs2069840, and rs2069861) were chosen so that
any marker that was not eventually chosen as a tagging marker was
already strongly correlated with at least one of the tagging markers
with r40.9.
Genotyping
Genotyping was performed using restriction fragment length
polymorphism or commercially available TaqMan-based assays
(Applied Biosystems, Foster City, CA, USA) (online Table S3).
Power calculation
For common SNPs with B30% MAF (which includes rs2069840
and rs1800795 (174G4C)), the power of our study exceeded 90,
80, and 70% when the odds ratio was 1.8, 1.7, and 1.6, respectively.
For less common SNPs with B10% MAF (rs1800796, rs2069837
and rs2069861), power was 80, 70, and 60% when the odds ratio was
2.0, 1.9, and 1.8, respectively. In haplotype analysis, our study has
substantial power (87%) to detect the association between the
GGGAGC risk haplotype and CRF/ESRD.
Statistical analysis
Data on the study groups were compared using w2 and Student’s
t-tests for categorical and continuous variables, respectively
(the SAS System for windows version 9.1; SAS Institute Inc., Cary,
NC, USA). Comparison of means across multiple groups
was performed using analysis of variance. Conformity of genotype
distributions to that expected under Hardy–Weinberg equilibrium
was assessed using w2 tests for goodness of fit. Estimation of haplo-
type frequencies was performed using the expectation–maximization
algorithm.28 Statistical significance of haplotype association with
disease was evaluated using a score test based on unphased
genotypic data.29 A P-value of o0.05 was considered statistically
significant after correction for the number of genotype and
haplotype comparisons.
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